Axogen Inc (AXGN)

$18.09 -0.34 (-1.84%)
Market Cap 811.07M
Revenue (ttm) 159.01M
Net Income (ttm) -21.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13.66%
Debt to Equity Ratio 0.48
Volume 668,700
Avg Vol 441,158
Day's Range N/A - N/A
Shares Out 44.01M
Stochastic %K 82%
Beta 1.01
Analysts Strong Sell
Price Target $18.00

Latest News on AXGN

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 10, 2025, 5:00 PM EST - 8 days ago

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Axogen: Well Placed To Capitalize Growth At Higher Multiples

Jan 6, 2025, 8:01 PM EST - 11 days ago

Axogen: Well Placed To Capitalize Growth At Higher Multiples

Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 9:53 AM EST - 2 months ago

Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Sep 6, 2024, 7:00 AM EDT - 4 months ago

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 2:10 PM EDT - 5 months ago

Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript

Axogen, Inc. Announces New Leadership Appointments

Aug 8, 2024, 7:05 AM EDT - 5 months ago

Axogen, Inc. Announces New Leadership Appointments

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Jul 23, 2024, 7:00 AM EDT - 6 months ago

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jul 1, 2024, 7:00 AM EDT - 7 months ago

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

Jun 24, 2024, 7:00 AM EDT - 7 months ago

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

May 28, 2024, 4:30 PM EDT - 8 months ago

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript

May 5, 2024, 1:21 AM EDT - 9 months ago

AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript

Axogen, Inc Reports First Quarter 2024 Financial Results

May 2, 2024, 7:00 AM EDT - 9 months ago

Axogen, Inc Reports First Quarter 2024 Financial Results

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Apr 29, 2024, 4:50 PM EDT - 9 months ago

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Apr 16, 2024, 7:00 AM EDT - 9 months ago

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 11:03 AM EST - 11 months ago

AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Mar 5, 2024, 7:00 AM EST - 11 months ago

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Feb 13, 2024, 4:30 PM EST - 1 year ago

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Feb 2, 2024, 4:15 PM EST - 1 year ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Jan 18, 2024, 5:00 PM EST - 1 year ago

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Jan 4, 2024, 4:45 PM EST - 1 year ago

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Jan 4, 2024, 4:40 PM EST - 1 year ago

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Axogen Announces Promotions on Research and Development Team

Jan 4, 2024, 4:35 PM EST - 1 year ago

Axogen Announces Promotions on Research and Development Team

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Dec 26, 2023, 4:15 PM EST - 1 year ago

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Axogen Announces Transition of Finance Team Leadership

Dec 6, 2023, 7:00 AM EST - 1 year ago

Axogen Announces Transition of Finance Team Leadership

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 1, 2023, 5:00 PM EST - 1 year ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AxoGen, Inc. (AXGN) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 9:49 AM EST - 1 year ago

AxoGen, Inc. (AXGN) Q3 2023 Earnings Call Transcript

Axogen, Inc. Reports 2023 Third Quarter Financial Results

Nov 7, 2023, 7:00 AM EST - 1 year ago

Axogen, Inc. Reports 2023 Third Quarter Financial Results

Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023

Oct 18, 2023, 7:00 AM EDT - 1 year ago

Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™

Sep 5, 2023, 7:00 AM EDT - 1 year ago

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™

Axogen to Participate at Upcoming Investor Conferences

Aug 31, 2023, 7:00 AM EDT - 1 year ago

Axogen to Participate at Upcoming Investor Conferences

Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio

Aug 21, 2023, 7:00 AM EDT - 1 year ago

Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio

AxoGen, Inc. (AXGN) Q2 2023 Earnings Call Transcript

Aug 7, 2023, 9:34 PM EDT - 1 year ago

AxoGen, Inc. (AXGN) Q2 2023 Earnings Call Transcript

Axogen, Inc. Reports 2023 Second Quarter Financial Results

Aug 7, 2023, 4:01 PM EDT - 1 year ago

Axogen, Inc. Reports 2023 Second Quarter Financial Results

Axogen to Participate at Canaccord Genuity's 43rd Annual Growth Conference

Jul 27, 2023, 7:00 AM EDT - 1 year ago

Axogen to Participate at Canaccord Genuity's 43rd Annual Growth Conference

Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023

Jul 26, 2023, 7:00 AM EDT - 1 year ago

Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023

AxoGen: Far More Constructive With Q1 Numbers, Profitability The Next Hurdle

Jun 23, 2023, 2:49 AM EDT - 1 year ago

AxoGen: Far More Constructive With Q1 Numbers, Profitability The Next Hurdle

Axogen to Participate at Jefferies Healthcare Conference

May 24, 2023, 7:00 AM EDT - 1 year ago

Axogen to Participate at Jefferies Healthcare Conference

AxoGen, Inc. (AXGN) Q1 2023 Earnings Call Transcript

May 9, 2023, 10:58 AM EDT - 1 year ago

AxoGen, Inc. (AXGN) Q1 2023 Earnings Call Transcript

Axogen, Inc. Reports 2023 First Quarter Financial Results

May 9, 2023, 7:00 AM EDT - 1 year ago

Axogen, Inc. Reports 2023 First Quarter Financial Results

Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023

Apr 18, 2023, 4:05 PM EDT - 1 year ago

Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023

AxoGen, Inc. (AXGN) Q4 2022 Earnings Call Transcript

Mar 14, 2023, 11:40 AM EDT - 2 years ago

AxoGen, Inc. (AXGN) Q4 2022 Earnings Call Transcript

Axogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial Results

Mar 14, 2023, 7:00 AM EDT - 2 years ago

Axogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial Results

AxoGen Making Progress, But Not Enough To Drive A Meaningful Rerating Yet

Mar 6, 2023, 2:26 PM EST - 2 years ago

AxoGen Making Progress, But Not Enough To Drive A Meaningful Rerating Yet

Axogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel

Mar 6, 2023, 7:00 AM EST - 2 years ago

Axogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel

Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023

Mar 2, 2023, 4:00 PM EST - 2 years ago

Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023

Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer

Feb 13, 2023, 7:00 AM EST - 2 years ago

Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022

Jan 9, 2023, 7:00 AM EST - 2 years ago

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022

Axogen to Participate at J.P. Morgan 41st Annual Healthcare Conference

Jan 4, 2023, 7:00 AM EST - 2 years ago

Axogen to Participate at J.P. Morgan 41st Annual Healthcare Conference

Axogen Patient to Ride the 2023 Donate Life Rose Parade® Float Supporting awareness of organ and tissue donation

Dec 19, 2022, 7:00 AM EST - 2 years ago

Axogen Patient to Ride the 2023 Donate Life Rose Parade® Float Supporting awareness of organ and tissue donation

AxoGen, Inc. (AXGN) Q3 2022 Earnings Call Transcript

Nov 8, 2022, 10:40 AM EST - 2 years ago

AxoGen, Inc. (AXGN) Q3 2022 Earnings Call Transcript